Mylan begins shipping generic version of Glaxo antidepressant Wellbutrin SR after FDA approval

Mylan launches generic version of Wellbutrin SR

PITTSBURGH — Mylan Inc. said Monday it started shipping a generic version of the antidepressant Wellbutrin SR after getting approval from the Food and Drug Administration.

The FDA cleared Mylan’s version of the drug in 100 milligram, 150 milligram and 200 milligram doses, Mylan said. The brand-name version of Wellbutrin SR is made by GlaxoSmithKline, and U.S. sales totaled $363 million in 2009.

Wellbutrin SR is the extended-release version of Wellbutrin, an older GlaxoSmithKline drug. Mylan said generic versions of Wellbutrin SR have been on the market for several years.

In afternoon trading, Mylan stock rose 6 cents to $22.60. Shares of GlaxoSmithKline were unchanged at $39.20.

(This version CORRECTS the story to note that generic versions of Wellbutrin SR are already available.)